SUSTAINED ERYTHROPOIETIC RESPONSE IN A PATIENT WITH MYELOFIBROSIS RECEIVING CONCOMITANT RUXOLITINIB AND DEFERASIROX

被引：0
|
作者：
Piro, E. [1 ]
Kropp, M. [1 ]
Lentini, M. [1 ]
Levato, L. [1 ]
Magro, D. [1 ]
Molica, S. [1 ]
机构：
[1] Azienda Osped Pugliese Ciaccio, Dipartimento Ematoncol, Catanzaro, Italy
来源：
HAEMATOLOGICA | 2017年 / 102卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
P114
引用
收藏
页码：97 / 97
页数：1
相关论文
共 50 条
  • [1] Sustained Erythroid Response in a Patient with Myelofibrosis Receiving Concomitant Treatment with Ruxolitinib and Deferasirox
    Piro, Eugenio
    Lentini, Maria
    Levato, Luciano
    Russo, Antonio
    Molica, Stefano
    CHEMOTHERAPY, 2018, 63 (02) : 107 - 110
  • [2] Mayor Erythropoietic Response after Deferasirox Treatment in a Transfusion-Dependent Anemic Patient with Primary Myelofibrosis
    Lisette, Del Corso
    Enrico, Balleari
    Eleonora, Arboscello
    Riccardo, Ghio
    Manilo, Mencoboni
    Omar, Racchi
    CASE REPORTS IN HEMATOLOGY, 2013, 2013
  • [3] Concomitant Treatment with Ruxolitinib and Deferasirox in the Management of Iron Overload in Patients with Myelofibrosis: A Multicenter Italian Experience
    Elli, Elena Maria
    Di Veroli, Ambra
    Iurlo, Alessandra
    Carmosino, Ida
    Benevolo, Giulia
    Abruzzese, Elisabetta
    Bonifacio, Massimiliano
    Sutto, Emanuele
    Polverelli, Nicola
    Caramella, Marianna
    Cilloni, Daniela
    Tiribelli, Mario
    Caocci, Giovanni
    Crisa, Elena
    Porrini, Raffaele
    Renso, Rossella
    Markovic, Uros
    Cattaneo, Daniele
    Biale, Lucia
    Ansuinelli, Michela
    Trawinska, Malgorzata Monika
    Scaffidi, Luigi
    Breccia, Massimo
    Gambacorti-Passerini, Carlo
    Palumbo, Giuseppe A.
    Latagliata, Roberto
    BLOOD, 2019, 134
  • [4] Successful pregnancy outcome in a patient with myelofibrosis receiving ruxolitinib treatment in the first trimester
    Urosevic, Ivana
    Dokic, Marina
    Percic, Ivanka
    El Farra, Amir
    Bjelogrlic, Dunja
    Sekulic, Borivoj
    LEUKEMIA & LYMPHOMA, 2024, 65 (10) : 1535 - 1537
  • [5] Practical management of patients with myelofibrosis receiving ruxolitinib
    Harrison, Claire
    Mesa, Ruben
    Ross, David
    Mead, Adam
    Keohane, Clodagh
    Gotlib, Jason
    Verstovsek, Srdan
    EXPERT REVIEW OF HEMATOLOGY, 2013, 6 (05) : 511 - 523
  • [6] Verruconis gallopava in a patient with myelofibrosis on ruxolitinib
    Hsu, Andrew
    Ulici, Veronica
    BLOOD, 2020, 135 (14) : 1189 - 1189
  • [7] Mutation landscape in patients with myelofibrosis receiving ruxolitinib or hydroxyurea
    Pacilli, Annalisa
    Rotunno, Giada
    Mannarelli, Carmela
    Fanelli, Tiziana
    Pancrazzi, Alessandro
    Contini, Elisa
    Mannelli, Francesco
    Gesullo, Francesca
    Bartalucci, Niccolo
    Fattori, Giuditta Corbizi
    Paoli, Chiara
    Vannucchi, Alessandro M.
    Guglielmelli, Paola
    BLOOD CANCER JOURNAL, 2018, 8
  • [8] Mutation landscape in patients with myelofibrosis receiving ruxolitinib or hydroxyurea
    Annalisa Pacilli
    Giada Rotunno
    Carmela Mannarelli
    Tiziana Fanelli
    Alessandro Pancrazzi
    Elisa Contini
    Francesco Mannelli
    Francesca Gesullo
    Niccolò Bartalucci
    Giuditta Corbizi Fattori
    Chiara Paoli
    Alessandro M. Vannucchi
    Paola Guglielmelli
    Blood Cancer Journal, 8
  • [9] Cemiplimab and ruxolitinib in concomitant cutaneous squamous cell carcinoma and myelofibrosis
    Di Raimondo, Cosimo
    Rao, Ludovico
    Lozzi, Flavia
    Lombardo, Paolo
    Silvaggio, Dionisio
    Vellucci, Laura
    Tofani, Lorenzo
    Campione, Elena
    Bianchi, Luca
    DERMATOLOGIC THERAPY, 2022, 35 (05)
  • [10] EFFICACY AND SAFETY OF DEFERASIROX IN THE MANAGEMENT OF IRON OVERLOAD IN MYELOFIBROSIS ALSO IN PATIENTS TREATED WITH RUXOLITINIB
    Elli, E. M.
    Aroldi, A.
    Renso, R.
    Carrer, A.
    Gambacorti-Passerini, C.
    HAEMATOLOGICA, 2017, 102 : 98 - 99
12345